Table I.

General characteristics of the patients with MM.

Age, in years; median (Q1-Q3)	67.5 (61.75-77.5)
Male/female, n (%)	19 (59.4)/13 (40.6)
MRI results, n (%)
Normal marrow	10 (31.3)
Focal lesions	11 (34.4)
Focal and diffuse infiltration	11 (34.4)
Disease stage (pre-therapeutic), n (%)
1	5 (15.6)
2	6 (18.8)
3	21 (65.6)
Treatment, n (%)
BD	19 (59.4)
VAD	13 (40.6)
Evolution, n (%)
Complete remission	9 (28.1)
Partial remission	5 (15.6)
Stable disease	7 (21.9)
Progressive disease	11 (34.4)
Survival, in months; median (Q1-Q3)	15.5 (10.5-24)

MM, multiple myeloma; MRI, magnetic resonance imaging; VAD, vincristine, doxorubicin and dexamethasone; BD, bortezomib and dexamethasone.